|
KMID : 0980120180160010007
|
|
Annals of Phlebology
2018 Volume.16 No. 1 p.7 ~ p.15
|
|
|
Practical Considerations in Choosing Non-Vitamin K Antagonist Oral Anticoagulants
|
|
Kim Jee-Young
Kim Hyang-Kyoung
|
|
|
Abstract
|
|
|
|
Four non-vitamin K antagonist oral anticoagulants (NOACs) are available in Korea, comprising a direct thrombin inhibitor (dabigatran) and three direct inhibitors of factor Xa (rivaroxaban, apixaban and edoxaban). Clinical trials involving patients with venous thromboembolism showed NOACs to have efficacy in preventing thromboembolic and thrombotic events comparable to that of warfarin with clear benefits over warfarin by reducing incidence of major bleeding. It is not clear that any of the NOACs is significantly better than the others in terms of efficacy and safety in any specific indications, in the absence of direct comparative head-to-head trials. However, their properties are not identical to each other and clinicians often encounter patients with various medical histories which needs careful selection of most appropriate NOAC. We aim to collect evidences from current studies to support the most suitable NOACs for an individual patient in a specific situation.
|
|
|
KEYWORD
|
|
|
Non-vitamin K antagonist oral anticoagulants, Dabigatran, Rivaroxaban, Apixaban, Edoxaban
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|